Collateral likes the angiogenesis treadmill

Although Chiron Corp. may have concluded that treadmill exercise time might not be the best end point for testing angiogenesis compounds in cardiovascular conditions, Collateral Therapeutics Inc. believes that the treadmill has successfully pointed it toward pivotal studies of its gene therapy for angina.

CHIR's fibroblast growth factor-2

Read the full 479 word article

How to gain access

Continue reading with a
two-week free trial.